These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8198022)

  • 1. Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment.
    Muratti EN; Peters TK; Leitersdorf E
    Am J Cardiol; 1994 May; 73(14):30D-38D. PubMed ID: 8198022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E; Muratti EN; Eliav O; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.
    Eliav O; Schurr D; Pfister P; Friedlander Y; Leitersdorf E
    Am J Cardiol; 1995 Jul; 76(2):76A-79A. PubMed ID: 7604804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
    Leitersdorf E; Muratti EN; Eliav O; Meiner V; Eisenberg S; Dann EJ; Sehayek E; Peters TK; Stein Y
    Am J Med; 1994 May; 96(5):401-7. PubMed ID: 8192170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study). French-Dutch Fluvastatin Study Group.
    Jacotot B; Banga JD; Waite R; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):41A-46A. PubMed ID: 7604796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
    Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
    Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database.
    Peters TK
    Am J Cardiol; 1995 Jul; 76(2):71A-75A. PubMed ID: 7604803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
    Greten H; Beil FU; Schneider J; Weisweiler P; Armstrong VW; Keller C; Klör HU; von Hodenberg E; Weidinger G; Eskötter H
    Am J Med; 1994 Jun; 96(6A):55S-63S. PubMed ID: 8017468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients.
    Sprecher DL; Abrams J; Allen JW; Keane WF; Chrysant SG; Ginsberg H; Fischer JJ; Johnson BF; Theroux P; Jokubaitis L
    Ann Intern Med; 1994 Apr; 120(7):537-43. PubMed ID: 8093139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia.
    Leitersdorf E; Eisenberg S; Eliav O; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Peters TK; Muratti EN
    Eur J Clin Pharmacol; 1993; 45(6):513-8. PubMed ID: 8157036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
    Zavoral JH; Haggerty BJ; Winick AG; Bergmann SD
    Am J Cardiol; 1995 Jul; 76(2):37A-40A. PubMed ID: 7604795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.
    Koizumi J; Haraki T; Yagi K; Inazu A; Kajinami K; Miyamoto S; Ueda K; Ohta M; Takegoshi T; Takeda M
    Am J Cardiol; 1995 Jul; 76(2):47A-50A. PubMed ID: 7604797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
    Betteridge DJ; Durrington PN; Fairhurst GJ; Jackson G; McEwan MS; McInnes GT; Miller JP; Mir MA; Reckless JP; Rees-Jones DI
    Am J Med; 1994 Jun; 96(6A):45S-54S. PubMed ID: 8017467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The efficacy, safety and tolerance of fluvastatin sodium 40 mg in patients with hyperlipidemia type IIA].
    Fanghänel Salmón G; Salgado Loza JL; Sánchez Reyes L; Padilla Retana JA; Espinosa Campos J
    Arch Inst Cardiol Mex; 1996; 66(2):151-6. PubMed ID: 8768633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
    Spieker LE; Noll G; Hannak M; Lüscher TF
    J Cardiovasc Pharmacol; 2000 Mar; 35(3):361-5. PubMed ID: 10710119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
    Sasaki S; Nakagawa M; Nakata T; Endo N; Miyao K; Kitamura K; Fukuyama M; Kitani T; Yamada C
    Cardiology; 1997; 88(2):160-5. PubMed ID: 9096917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.